200
Participants
Start Date
May 10, 2022
Primary Completion Date
December 3, 2022
Study Completion Date
December 3, 2022
Tafenoquine prophylaxis
"The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
108 Military Central Hospital, Hanoi
Lead Sponsor
Naval Medical Research Unit TWO (NAMRU-2)
UNKNOWN
Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI)
UNKNOWN
The 108 Military Central Hospital
OTHER_GOV
Naval Environmental Preventive Medicine Unit TWO (NEPMU-2)
UNKNOWN
Naval Medical Research Center
FED